NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis $23.72 -0.04 (-0.17%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$23.58▼$24.6850-Day Range$20.65▼$25.5652-Week Range$18.61▼$29.40Volume478,767 shsAverage Volume703,489 shsMarket Capitalization$1.81 billionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside15.9% Upside$27.50 Price TargetShort InterestBearish4.08% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment0.92Based on 6 Articles This WeekInsider TradingSelling Shares$382,807 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.05) to $0.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector351st out of 936 stocksMedical Laboratories Industry10th out of 18 stocks 2.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 1 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.08% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Veracyte has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 66.88% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 3.3 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Veracyte this week, compared to 3 articles on an average week.MarketBeat Follows5 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,807.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.05) to $0.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -25.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -25.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesJuly 19, 2024 | insidertrades.comInsider Selling: Veracyte, Inc. (NASDAQ:VCYT) Insider Sells 1,277 Shares of StockJuly 24 at 10:57 AM | investorplace.comThe 3 Best Personalized Nutrition Stocks to Buy NowJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 23 at 2:44 AM | nz.finance.yahoo.comVERACYTE INC. DL-,001 (12V.MU)July 20, 2024 | americanbankingnews.comJohn Leite Sells 1,277 Shares of Veracyte, Inc. (NASDAQ:VCYT) StockJuly 20, 2024 | americanbankingnews.comInsider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells 7,500 Shares of StockJuly 19, 2024 | finance.yahoo.comInsider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)May 28, 2024 | finance.yahoo.comVeracyte (VCYT) Fell Due to a Lack of Rising ProfitabilityJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 22, 2024 | businesswire.comVeracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerMay 10, 2024 | markets.businessinsider.comVeracyte’s Robust Performance and Growth Potential Reinforce Buy RatingMay 10, 2024 | markets.businessinsider.comVeracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy RatingMay 9, 2024 | finance.yahoo.comIs Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?May 8, 2024 | markets.businessinsider.comMaintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward ProfitabilityMay 8, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comVeracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...May 7, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test PerformanceMay 7, 2024 | seekingalpha.comVeracyte, Inc. 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees815Year Founded2006Price Target and Rating Average Stock Price Target$27.50 High Stock Price Target$34.00 Low Stock Price Target$21.00 Potential Upside/Downside+15.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-18.16% Pretax Margin-18.76% Return on Equity-1.42% Return on Assets-1.33% Debt Debt-to-Equity RatioN/A Current Ratio5.00 Quick Ratio4.69 Sales & Book Value Annual Sales$361.05 million Price / Sales5.02 Cash Flow$0.09 per share Price / Cash Flow252.34 Book Value$14.30 per share Price / Book1.66Miscellaneous Outstanding Shares76,450,000Free Float75,454,000Market Cap$1.81 billion OptionableOptionable Beta1.65 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.55MMs. Rebecca Chambers (Age 46)Executive VP & CFO Comp: $901.49kDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Comp: $657.74kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $791.72kDr. John Leite Ph.D. (Age 52)Chief Commercial Officer for CLIA Business Comp: $1.53MMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerMs. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Ms. Corinne DananSenior Vice PresidentMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHRadNetNASDAQ:RDNTGuardant HealthNASDAQ:GHFortreaNASDAQ:FTREViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 233,486 shares on 7/26/2024Ownership: 8.907%Bank of New York Mellon CorpBought 31,613 shares on 7/26/2024Ownership: 0.369%EFG Asset Management North America Corp.Sold 13,510 shares on 7/26/2024Ownership: 0.319%Allspring Global Investments Holdings LLCBought 1,740 shares on 7/26/2024Ownership: 0.014%AMI Asset Management CorpSold 117,327 shares on 7/25/2024Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions How have VCYT shares performed this year? Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT shares have decreased by 13.8% and is now trading at $23.72. View the best growth stocks for 2024 here. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. Veracyte's revenue for the quarter was up 17.5% on a year-over-year basis. Does Veracyte have any subsidiaries? The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS. Who are Veracyte's major shareholders? Veracyte's top institutional shareholders include ARK Investment Management LLC (8.91%), Sumitomo Mitsui Trust Holdings Inc. (4.16%), Bank of New York Mellon Corp (0.37%) and EFG Asset Management North America Corp. (0.32%). Insiders that own company stock include John Leite, Giulia C Kennedy, Evan/ Fa Jones, Bonnie H Anderson, Karin Eastham, John L Bishop and Jens Holstein. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). This page (NASDAQ:VCYT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
